Kidney Transplantation Clinical Trial
Official title:
Pharmacokinetic Evaluation of Plasmapheresis in Cross Match Positive or ABO Incompatible Kidney Allograft Recipients
Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy. The researchers are also interested in evaluating the pharmacokinetics of the various immunosuppressant medications that patients will receive such as tacrolimus, mycophenolate mofetil and daclizumab.
Kidney transplantation has emerged as a desired treatment of choice for patients with end
stage renal disease. Although transplantation has become increasingly successful, there
continues to be risks associated with it. Prior to performing a kidney transplant patients
are cross-matched (a test to determine whether or not they have preformed antibodies to the
donor). Preformed antibodies result from a previous pregnancy, blood or platelet transfusion
or prior transplant. Performing a transplant in patients who have preformed antibodies
against the donor generally results in hyperacute rejection (when the immune system attacks
the new kidney). This hyperacute rejection usually results in kidney loss in a very high
percentage of patients. Due to these consequences, pre-transplant cross-matching has emerged
as a standard of care. Although hyperacute kidney loss has now been avoided, a large
population of highly sensitized patients that has little hope of receiving a transplant has
been identified.
A number of groups have studied methods to lower specific antibody levels in a variety of
clinical settings. The two primary methods used today in transplantation are plasmapheresis
(the separation of plasma from cells, and the removal of solutes, immune globulins, and
medications) and administration of immune globulin therapy. Employing either of these
techniques individually or jointly has substantially reduced acute rejection and improved
kidney survival in these highly sensitized patients. The immune globulin treatments that
have been studied have included large variations in dosage as well as differences in immune
globulin products. The results from these small studies have not identified one therapy,
product or dosage that could be considered standard of care.
The kidney transplant work-up also consists of matching ABO blood group between donor and
recipient. Transplantation against the recipient blood group has resulted in very poor
outcomes due to antibody mediated rejection (when the immune system attacks the kidney).
However, due to the shortage of organs available for transplantation, the increasing number
of patients awaiting a transplant and the favorable outcomes with live donor transplant,
some transplant programs have developed protocols for transplanting against the recipient
ABO blood group. These protocols are centered around plasmapheresis and treatment with
immune globulin. As with the positive cross-match patients stated earlier, the standard of
care has yet to be identified.
Dr. Lloyd Ratner, currently at Columbia University and former Chief of Transplant at Thomas
Jefferson University Hospital and his former colleagues at Johns Hopkins University have
studied the use of plasmapheresis in combination with Cytomegalovirus Immune Globulin
Intravenous (CytoGam) to reverse a positive cross match and to transplant organs against ABO
incompatible blood groups. This has enabled over 20 kidney transplants to be performed with
patient and graft survival at one year being very similar to our traditional cross match
negative and ABO compatible patients. These results are generally considered outstanding
given the fact that antibody mediated rejection historically had a 75 to 100% incidence of
graft loss.
The treatment protocol that is used consists of plasmapheresis treatments alternating with
CytoGam infusions every other day for 3 to 9 treatments prior to transplantation and another
1-5 treatments after transplant. Plasmapheresis is increasingly performed to treat various
infectious, immunological, metabolic and inherited diseases. In this procedure, plasma and
cellular components of blood are separated and solutes in plasma, including drugs may be
removed. Generally, a volume of 1 to 1.5 times the plasma volume is removed and replaced
with an equivalent volume of crystalloid or colloid. The procedure removes solutes or drugs
from the blood compartment and the tissue stores remain unaffected except for
re-equilibration with decreasing plasma concentrations. After each plasmapheresis treatment
patients receive an infusion of CytoGam which is used to "inactivate" the remaining
antibody. However, it is not known to what extent subsequent treatments of plasmapheresis
remove CytoGam that patients received only hours or days prior.
During the treatment phase with plasmapheresis patients also receive a number of other
medications such as immunosuppressants for the prevention and treatment of graft rejection,
antibiotics for prevention and treatment of infection and various other medications for
related illnesses. The effects that plasmapheresis may have on removal of these medications
is not known for many of these agents. This information would be helpful for the potential
need to re-dose or give supplemental doses of medications. This is extremely important for
the immunosuppressant medications since under-dosing of these agents may result in serious
negative outcomes. Due to these many unknown aspects it would be useful to know the extent
of drug removal during plasmapheresis treatments. This would enable more precise dosing and
ultimately better patient care.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 |